{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"17.5","value":"7.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease progression as determined by the investigator. Participants who are alive or lost to follow-up will be censored on the last-known-to-be-alive date. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \\< 200 mg per 24 hours.","dispersionType":"80% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg IV + Daratumumab 16 mg/kg IV + Pomalidomide 4 mg/day Oral + Dexamethasone 40 mg Oral (20 mg for \\> 75 Years Old) administered within a 28-day cycle for a maximum of 22 cycles","id":"OG000","title":"PD3 Arm"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants with a partial response or better, who received at least 1 dose of the study medication, and who have measurable disease at baseline and at least 1 postbaseline efficacy assessment. Pre-specified for data to be collected only in the PD3 arm.","reportingStatus":"POSTED","timeFrame":"From the earliest date of documented response (PR or better) to earliest date of progressive disease (up to approximately 66 months)","title":"Kaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm","type":"SECONDARY","unitOfMeasure":"Months"}